News & Media

RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com.

Press Releases

All Verastem Oncology press releases are archived here.

Media Resources

Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers. These types of cancers—which include low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are extremely difficult to treat and currently available therapeutic options are limited and suboptimal. That’s why new options are needed, and we’re committed to delivering them.

 

For media interested in Verastem Oncology, please contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com. You can also refer to the resources below, which contain information about what we do, our leadership team and our financials.

 

 

To stay updated on the latest news about Verastem Oncology, sign up for alerts.

Articles Featuring Verastem Oncology

Contact

Lisa Buffington
Corporate Communications
(781) 292-4502
media@verastem.com

Tweets by @VerastemOncolog

#NSCLC patients face undeniable burdens. @AlexSpiraMDPhD of @VCSpecialists, talks about the need to find better and more targeted treatments and using comprehensive #BiomarkerTesting to improve patient outcomes. #LungCancerAwarenessMonth #LCAM #LCSM

If you have non-small cell #LungCancer, it's important to #KnowYourBiomarker. We're partnering with @LUNGevity this KNOWvember to spread awareness about biomarker testing. Learn how to start the conversation with your doctor #NoOneMissed #LCAM #LCSM